Medtronic (NYSE:MDT) announced today that it submitted 510(k) applications to the FDA seeking clearance for an interoperable insulin pump. Clearance would enable system integration with a continuous glucose monitor (CGM) sensor based on Abbott’s most advanced platform. This marks the latest development in a landmark collaboration between the two medtech giants. Last summer, the companies […]
Business/Financial News
Biolinq closes $100M Series C funding round for biosensor platform
Biolinq said today it has closed a $100 million Series C funding round to advance its biosensor platform. “This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device,” Biolinq CEO Rich Yang said in a […]
Ypsomed to sell diabetes business, insulin delivery tech to TecMed for $517.7M
Ypsomed announced today that it agreed to sell its diabetes care business to TecMed for up to approximately $517.7 million (CHF 420 million). Burgdorf, Switzerland–based Ypsomed says the sale helps it focus on strengthening its position in the subcutaneous self-injection market. TecMed — also based in Burgdorf — can now add Ypsomed’s insulin delivery technology […]
Tidepool achieves new certification for open-source quality management system
Tidepool announced today that it secured a new certification for its open-source quality management system, known as qmsOS. Palo Alto, California-based Tidepool, a non-profit diabetes data management group, develops open-source technology for the diabetes community. That includes the FDA-cleared Tidepool Loop, a “do-it-yourself” (DIY) automated insulin delivery (AID) system. Recent collaborations include integrations with Abbott and Sequel […]
Glucotrack to bring implantable CBGM to automated insulin delivery system initiative in Europe
Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe. FORGETDIABETES aims to develop a long-term automated insulin delivery system. This system should enable optimal glucose control without patient intervention. The initiative, funded by the European Union’s Horizon 2020 research and innovation program, offers support from basic research to […]
Satio, Nanowear collab to bring AI-powered biomarkers to drug delivery
Satio and Nanowear today announced that they partnered to advance patient-friendly, home-based diagnostic and therapeutic care. The collaboration aims to integrate Nanowear’s at-home AI-based nanotechnology biomarker diagnostic platform with Satio’s at-home blood draw diagnostics and drug delivery systems/patches. This would combine time-synchronous, in vivo and in vitro diagnostics for precision therapeutics and individualized AI-based risk […]
Tidepool founder and CEO is stepping down
Howard Look announced that he is stepping down from his role as CEO at automated insulin delivery technology developer Tidepool. Look, who co-founded the Palo Alto, California-based company in 2013, shared the news on LinkedIn. “After 12 incredible years, I’m stepping back from my role as CEO of Tidepool,” he wrote. “It’s hard to put […]
Retractable Technologies cuts workforce as it reduces reliance on China amid trade war
Retractable Technologies (NYSE:RVP) announced today that it reduced its workforce by approximately 7%. The Little Elm, Texas-based maker of products like syringes and needles said the move comes as it allocates more resources to the U.S. It aims to increase U.S. manufacturing capabilities and reduce reliance on products produced in China. According to a news […]
Dexcom wins FDA nod for 15-day CGM
Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system. The clearance covers people over the age of 18 years old in the U.S. It makes the G7, Dexcom’s latest-generation CGM, the longest-lasting wearable CGM, according to the company. San Diego–based Dexcom submitted its 15-day G7 CGM to the […]
Doctors issue call to action to eliminate barriers to automated insulin delivery
Key opinion leaders issued a call to action to the diabetes community to recognize the importance of automated insulin delivery (AID). A number of doctors issued this call, published by Mary Ann Liebert’s Diabetes Technology & Therapeutics, to implement the advances made in the AID technology space. They say pivotal trials and real-world data support […]
